The Hydroponics Company Ltd (ASX:THC) Australian Patients Can Now Access Endoca Medicinal Cannabis


Sydney, July 31, 2018 AEST (ABN Newswire) – The Hydroponics Company Limited (ASX:THC) (OTCMKTS:HDRPF) (THC or the Company), Australia’s leading medicinal cannabis company(see Note below) advises that THC’s wholly owned subsidiary, Canndeo Limited, has released its first medicinal cannabis products, imported from the Company’s European strategic alliance partner, Endoca. The products are available through the Medicinal Cannabis Medicines Portal (MCMP: mcmp.com.au) under the Approved Prescriber and Special Access Schemes.

Key Points

– Endoca Medicinal Cannabis, imported by the Company now available to patients through the Medicinal Cannabis Medicines Portal

– Products available include Endoca’s CBD and unique CBD+CBDA formulations

– Immediate patient access through the Approved Prescriber and Special Access Schemes

– Company advancing medicinal cannabis strategy – imported product followed by domestic production using pharmaceuticals manufacturing facility and growing capability

Canndeo is a founding partner of MCMP, developed by Sinapse Pty Ltd, a leader in pharmaceutical IT systems, which provides a streamlined process for medicinal cannabis prescribing and dispensing between health professionals and manufacturers of medicinal cannabis.

MCMP ensures a continuity of care between patients, carers, and their existing health professionals.

Pharmacies and prescribers can use MCMP to access THC imported Endoca oil products in both CBD and Endoca’s unique CBD+CBDA formulations. To assist pharmacies and prescribers, Canndeo and Sinapse have made available various clinical materials and information on MCMP to registered prescribers and pharmacies.

Chief Executive Officer, Ken Charteris commented:

“We are pleased to now be delivering high quality medicinal cannabis products to the Australian market through MCMP having leveraged our global commercial partnerships, including Endoca and Sinapse.

“Using MCMP reduces the administrative burden on prescribing doctors and pharmacies, which is currently a key challenge for the prescribing of medicinal cannabis in Australia. We look forward to seeing the first patients using product supplied by THC in the coming weeks.

“Bringing product to the Australian market is a key step in the execution of our medicinal cannabis strategy, with imported product to be followed by THC’s domestic production taking advantage of our industry leading pharmaceuticals manufacturing facility and significant growing capacity.”

Note: Assessment based on key peers (CAN, AC8) comparison matrix

About The Hydroponics Company Ltd

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Blaise Bratter
Blaise Bratter is the Chief Contributor to CannabisIntel. Being involved in the Australian cannabis industry since legalisation in 2016, he is now Operations Manager for ASX listed company MGC Pharmaceuticals.

Get all the latest content delivered straight to your inbox.”